Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database

OBJECTIVE: Anti–tumor necrosis factor (anti‐TNF) medications are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently, anti‐TNF agents are often discontinued early in gestation. Certolizumab pegol (CZP), a PEGylated,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arthritis Rheumatol
Auteurs principaux: Clowse, Megan E. B., Scheuerle, Angela E., Chambers, Christina, Afzali, Anita, Kimball, Alexa B., Cush, John J., Cooney, Maureen, Shaughnessy, Laura, Vanderkelen, Mark, Förger, Frauke
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Rheumatoid Arthritis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174965/
https://ncbi.nlm.nih.gov/pubmed/29623679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40508
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires